Lexeo Therapeutics, Inc.
LXEO evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $357.7M
- Lead Asset:
- lx1001 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for LXEO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LXEO
Lexeo Therapeutics is a clinical-stage genetic medicine company developing AAVrh10-based gene therapies for cardiac and neurodegenerative diseases, with lead programs in Friedreich ataxia cardiomyopathy (LX2006) and arrhythmogenic cardiomyopathy (LX2020).
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$357.7M
Cash Runway
—
Lead Asset
lx1001 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 8 clinical trials for Lexeo Therapeutics, Inc..
Lexeo Therapeutics is a clinical-stage genetic medicine company developing AAVrh10-based gene therapies for cardiac and neurodegenerative diseases, with lead programs in Friedreich ataxia cardiomyopathy (LX2006) and arrhythmogenic cardiomyopathy (LX2020).
- Cash and equivalents of $92.8M as of 2026-06-30 [sec].
- Net loss of $25.9M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $235.1M as of 2026-06-30 [sec].
- LX2006 has received Breakthrough Therapy, Fast Track, Orphan Drug, RMAT, and Rare Pediatric Disease designations from the FDA [pipeline].
- LX2020 received RMAT designation based on interim clinical data [news].
What works
- LX2006 has secured multiple FDA designations (Breakthrough Therapy, Fast Track, Orphan Drug, RMAT, Rare Pediatric Disease), indicating regulatory support for accelerated development [pipeline].
- LX2020 interim data showed dose-dependent increases in PKP2 protein expression (93% mean increase in low-dose, 162% in high-dose cohorts) and was generally well tolerated [sec_mda · as of 2026-03-30].
- The company has a cash position of $92.8M as of 2026-06-30, providing a multi-year runway to advance clinical programs [sec].
What to weigh
- Lexeo has not generated any revenue from product sales since inception and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-03-30].
- The company will require substantial additional funding to support ongoing operations, with expenses expected to increase significantly as clinical trials advance [sec_mda · as of 2026-03-30].
- LX1001 (Alzheimer's gene therapy) faces a highly competitive landscape with 49 competitors, including Phase 3 programs from large pharma [pipeline].
From the filings
Quoted directly from source documents.
LX2020 showed dose-dependent PKP2 protein increases and was well tolerated.
“Increases in PKP2 protein expression versus baseline at three months in all participants that had undergone cardiac biopsies (n=7) assessed by western blot. Dose-dependent increases observed, with mean increase of 93% in the low-dose cohort (n=2) and 162% mean increase in the high-dose cohorts (n=5). Based on the data observed as of the October 2025 and January 2026 readouts, LX2020 remained generally well tolerated with no clinically significant complement activation.”
SEC MD&A · March 30, 2026
LX2006 topline data expected in second half of 2027.
“topline data expected in second half of 2027”
News · August 12, 2026
FDA granted RMAT designation for LX2020.
“FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM”
News · August 12, 2026
Catalyst timeline
- 2022-08-24 · Phase 2 start for LX2006 (Friedreich Ataxia cardiomyopathy) — Initiated a Phase 1/2 study of LX2006 in participants with cardiomyopathy associated with Friedreich's Ataxia.
- 2024-02-29 · Phase 2 start for LX2020 (PKP2-ACM) — Initiated a Phase 1/2 study of LX2020 in patients with arrhythmogenic cardiomyopathy due to a plakophilin-2 pathogenic variant.
- 2026-06-25 · Phase 2 start for SUNRISE-FA 2 (LX2006 pivotal trial) — Initiated a Phase 2, multicenter, open-label pivotal trial for LX2006 in Friedreich Ataxia cardiomyopathy.
Risks & what to watch (4)›
Key risks
- No revenue, ongoing losses — No product revenue since inception; expects significant operating losses for several more years [sec_mda · as of 2026-03-30].
- Substantial funding needed — Requires additional funding to support operations; expenses will increase with clinical development [sec_mda · as of 2026-03-30].
- Clinical trial execution risk — LX2006 topline data not expected until H2 2027; delays could impact timelines and funding [news].
- Competitive pressure for LX1001 — Alzheimer's gene therapy faces 49 competitors, including Phase 3 programs from large pharma [pipeline].
What to watch
- Topline data from the SUNRISE-FA 2 pivotal trial for LX2006 expected in the second half of 2027 [news].
- Enrollment progress and site activation for the SUNRISE-FA 2 study and CLARITY-FA trial [news].
- Any updates on LX2020's RMAT designation and potential accelerated approval pathway [news].
- Cash burn rate and any new financing rounds given the expectation of continued operating losses [sec_mda · as of 2026-03-30].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Lexeo Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lexeo Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08 · 0% dilution
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
0 buys · 9 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 18.0%
- Days to cover
- 13.1
- Shares short
- 12,497,266
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LXEO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lexeo Therapeutics, Inc.?
Lexeo Therapeutics is a clinical-stage genetic medicine company developing AAVrh10-based gene therapies for cardiac and neurodegenerative diseases, with lead programs in Friedreich ataxia cardiomyopathy (LX2006) and arrhythmogenic cardiomyopathy (LX2020).
What is Lexeo Therapeutics, Inc.'s lead drug candidate?
Lexeo Therapeutics, Inc.'s most advanced tracked candidate is lx1001 (Phase 1) for Alzheimer Disease.
Who is the CEO of Lexeo Therapeutics, Inc.?
Mr. R. Nolan Townsend M.B.A. is the chief executive officer of Lexeo Therapeutics, Inc. (LXEO).
Where is Lexeo Therapeutics, Inc. headquartered?
Lexeo Therapeutics, Inc. (LXEO) is headquartered in New York, NY, United States.
What therapeutic areas does Lexeo Therapeutics, Inc. focus on?
Lexeo Therapeutics, Inc. develops therapies across Rare Disease, Gene Therapy, Neurology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.